Apofore Founder Publishes Studies Identifying Apolipoprotein A-IV as New Potential Target for Type 2 Diabetes Therapeutics

Published: May 23, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apofore Corporation today announced that its scientific founder at the University of Cincinnati, Patrick Tso, PhD, Professor in the Department of Pathology and Laboratory Medicine, has published new data demonstrating that the naturally occurring protein, Apolipoprotein A-IV (apoA-IV), reduces blood sugar and increases insulin secretion in mouse models of diabetes. The research published in the current online early edition of the Proceedings of the National Academy of Sciences (PNAS), suggests apoA-IV is a promising new target for developing treatments for Type 2 diabetes. Apofore, which has licensed the technology from the university, is building on this work to develop novel Type 2 diabetes therapeutics, beginning with a recombinant form of apoA-IV.

Back to news